Antibacterial PDO suture line and preparation process thereof

Abstract

The invention belongs to the field of medical sutures, and particularly provides an antibacterial PDO suture and a preparation process thereof, and the preparation process comprises the following steps: taking PPDO particles, fully drying the PPDO particles, then carrying out melt spinning, then sequentially carrying out traction, corona and dipping treatment, and then washing and drying the PPDO particles to obtain the antibacterial PDO suture. The dipping treatment is carried out in a coating solution; the PDO suture line prepared after being treated by the coating liquid has the advantage of lasting antibacterial property, and slow degradation is beneficial to playing a long-term fixing role on a sutured wound.

Description

TECHNICAL FIELD

[0001] The application belongs to the technical field of medical sutures, and particularly relates to an antibacterial PDO suture and a preparation process thereof. BACKGROUND

[0002] PDO suture is a kind of absorbable medical material commonly used in surgical operations, and its main component is polydioxanone, which has excellent biocompatibility, biodegradability and mechanical stability. In clinical application, PDO suture can be gradually degraded and absorbed by the body through hydrolysis reaction in the body, without the need for secondary operation to remove it, effectively reducing the risk of postoperative complications, and at the same time, providing stable support for the wound healing process. It is one of the high-performance suture materials commonly used in clinical practice.

[0003] However, during the operation and postoperative wound healing stage, the suture as a foreign body implanted in the body is easy to become a carrier for bacterial attachment and breeding. After bacteria colonize on the surface of the suture, they will multiply and form a biofilm, which may damage the structural integrity of the suture and reduce its mechanical properties, thereby affecting the wound healing effect. On the other hand, bacterial breeding can cause local inflammatory reaction, and in severe cases, it can aggravate wound infection, causing symptoms such as redness, pus, and increased pain, and even causing systemic infection, threatening the life safety of patients. To solve the above problems, an antibacterial component-containing coating can be applied to the surface of the PDO suture, which can inhibit bacterial attachment and reproduction on the surface of the suture by using the bactericidal or bacteriostatic effect of the antibacterial component, thereby reducing the risk of suture damage and wound infection caused by bacterial invasion from the source.

[0004] The patent application file with the publication number CN120393087A discloses a triclosan antibacterial coating surgical suture and a preparation method thereof. In the scheme, the coating solution containing antibacterial components such as triclosan is uniformly coated on the surface of the substrate by dipping coating, electrospinning and spraying process. Through the formation of a synergistic system of triclosan, nano-silver and titanium dioxide, antibacterial effect can be achieved.

[0005] In the above-mentioned application file, although the introduction of antibacterial components such as triclosan can improve the antibacterial effect of the suture, the release effect of the antibacterial components from the coating is limited, and the adhesion of the obtained coating to the suture substrate may cause the coating to be lost prematurely and cause the degradation of the suture to be accelerated. Therefore, it is necessary to find an antibacterial suture and a preparation process thereof which can reduce the degradation rate of PDO suture and obtain long-lasting antibacterial effect. SUMMARY

[0006] In view of the above problems, in order to further reduce the degradation rate of PDO suture and obtain long-lasting antibacterial effect, the application provides an antibacterial PDO suture and a preparation process thereof.

[0007] This application first provides a process for preparing antibacterial PDO sutures, including the following steps:

[0008] PPDO granules are thoroughly dried and then melt-spun. The granules are subsequently subjected to drawing, corona treatment, and impregnation, followed by washing and drying. The impregnation treatment is carried out in a coating solution. The melt spinning temperature is set at 130℃-135℃, and the screw speed is 25-30 r / min. The drawing ratio is set at 3.7-4.2. The corona treatment is set with a current intensity of 1.8-2.3A, a power of 3000-4000W, and a corona treatment time of 2.8-3.5s.

[0009] The preparation steps of the coating liquid include the following:

[0010] S01. Take hyaluronic acid, carboxymethyl chitosan and sodium alginate, mix them, add water to disperse them, stir at room temperature overnight to obtain phase A for later use;

[0011] S02. Mix triclosan, alkali, and propyl gallate, add ethanol and sonicate to disperse, then add tributyl citrate and candelilla wax powder, continue sonication to obtain phase B for later use;

[0012] S03. Add phase B dropwise to phase A, then add chitosan quaternary ammonium salt aqueous solution, stir, then add dopamine hydrochloride aqueous solution, continue stirring, then adjust the pH, add genipin alcohol solution, stir the reaction in the dark, then cure at 4°C, and filter with 200 mesh filter cloth to obtain the final product.

[0013] Furthermore, in step S01, the mass-to-volume ratio of hyaluronic acid, carboxymethyl chitosan, sodium alginate, and water is (0.8-1)g:(0.5-0.8)g:(0.3-0.5)g:70mL.

[0014] Furthermore, in step S02, the mass-to-volume ratio of triclosan, alkali, propyl gallate, ethanol, tributyl citrate, and candelilla wax powder is (0.1-0.2)g:(0.05-0.1)g:(0.05-0.1)g:15mL:(0.4-0.5)g:(0.01-0.02)g.

[0015] Furthermore, in step S02, the ultrasonic power is set to 20-25 kHz.

[0016] Furthermore, in step S03, the dropping rate is controlled at 1.5-2 mL / min, and phase B is added to phase A; the mass concentration of chitosan quaternary ammonium salt in the chitosan quaternary ammonium salt aqueous solution is 6%-8%; the concentration of dopamine hydrochloride in the dopamine hydrochloride aqueous solution is 3.5%-5%; the mass concentration of genipin in the genipin alcohol solution is 0.5%-1%; and the pH is adjusted to 7.8-8.0.

[0017] This application also provides an antibacterial PDO suture, which is prepared using the above-described method.

[0018] Compared with the prior art, this application has the following beneficial effects:

[0019] 1. After corona treatment, the broken bond sites on the surface of PDO melt-spun precursor fibers can form an interlocking structure with the coating. At the same time, the potential sites excited by the corona treatment can attract the chitosan quaternary ammonium salt in the coating component, further promoting the adhesion of the coating to the PDO precursor fibers. Genipin in the coating component acts as a "molecular bridge" and promotes the chemical bonding between the coating and the PDO precursor fibers through covalent cross-linking. Polydopamine, through its catechol structure, forms extensive hydrogen bonds and π-π stacking interactions with various components, providing additional secondary binding forces. Finally, a stable interpenetrating interface network of "electrostatic-covalent-physical" interpenetration is constructed, realizing the integrated bonding between the coating and the PDO precursor fibers.

[0020] 2. Positively charged chitosan quaternary ammonium salt forms a complex structure with the phenolic hydroxyl groups of triclosan through electrostatic and hydrogen bonding, thus delaying its dissolution; berberine and propyl gallate form a composite microdomain through hydrophobic interaction and π-π stacking, encapsulating triclosan and reducing its diffusion rate; and the dense three-dimensional network formed by genipin crosslinking further restricts the free diffusion of triclosan. Through a multi-level sustained-release system, the resistance to the release of the antibacterial active component triclosan from the coating is enhanced, achieving a long-lasting antibacterial effect.

[0021] 3. The rigid aromatic heterocycle of berberine and the benzene ring of propyl gallate work together to construct a stable hydrophobic core region in the coating through hydrophobic interactions and molecular arrangement. Candelilla wax, as a natural highly hydrophobic material, fills and enhances the hydrophobic density of the coating. These hydrophobic components are firmly anchored in a stable network framework composed of crosslinked polydopamine and genipin, thereby forming a continuous and dense hydrophobic barrier throughout the coating, effectively blocking the penetration of water molecules from the bulk into the PDO inside the coating and delaying the hydrolysis of its ester bonds. Attached Figure Description

[0022] Figure 1 Data on the weight loss rate of PDO sutures in Examples 1-3 and Comparative Examples 1-2 of this application over time.

[0023] Figure 2The cumulative release data of triclosan on the PDO suture line of Examples 1-3 and Comparative Examples 1-2 of this application over 28 days are presented. Detailed Implementation

[0024] To make the inventive objectives, technical solutions, and beneficial effects of this application clearer, the following detailed description is provided in conjunction with embodiments. Obviously, the described embodiments are merely some, not all, of the embodiments described herein. All other embodiments obtained by those skilled in the art based on the embodiments of this application without inventive effort are within the scope of protection of this application.

[0025] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs. The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the application. The term "and / or" as used herein includes any and all combinations of one or more of the associated listed items.

[0026] When using “including,” “having,” and “contains” as described herein, the intention is to cover non-exclusive inclusion, unless an explicit qualifying term such as “only,” “consisting of,” etc., is used, in which case another component may be added.

[0027] The terms "preferred," "more preferably," "better," and "even better" used in this application refer to embodiments of this application that provide certain beneficial effects under certain circumstances. However, other embodiments may also be preferred under the same or other circumstances. Furthermore, the description of one or more preferred embodiments does not imply that other embodiments are unavailable, nor is it intended to exclude other embodiments from the scope of this application. That is, in this application, "preferred," "more preferably," "better," and "even better" are merely descriptions of implementations or embodiments with better effects, but do not constitute a limitation on the scope of protection of this application.

[0028] In this application, terms such as "further," "even more," and "particularly" are used for descriptive purposes and indicate differences in content, but should not be construed as limiting the scope of protection of this application.

[0029] In this application, "at least one" means one or more, such as one, two, or more. "Multiple" or "several" means at least two, such as two, three, etc., and "multi-layered" means at least two layers, such as two layers, three layers, etc., unless otherwise explicitly specified. In the description of this application, "several" means at least one, such as one, two, etc., unless otherwise explicitly specified.

[0030] When a numerical range is disclosed herein, the range is considered continuous and includes the minimum and maximum values ​​of the range, as well as every value between the minimum and maximum values. Furthermore, when the range refers to integers, it includes every integer between the minimum and maximum values ​​of the range. Additionally, when multiple ranges are provided to describe a feature or characteristic, the ranges may be combined. In other words, unless otherwise specified, all ranges disclosed herein should be understood to include any and all subranges to which they are incorporated.

[0031] Unless otherwise specified, all steps in this application may be performed sequentially or randomly. For example, the method comprising steps (a) and (b) indicates that the method may include steps (a) and (b) performed sequentially, or it may include steps (b) and (a) performed sequentially. For example, the mention that the method may also include step (c) indicates that step (c) may be added to the method in any order; for example, the method may include steps (a), (b), and (c), or it may include steps (a), (c), and (b), or it may include steps (c), (a), and (b), etc. Unless otherwise stated, singular terms may include plural forms and should not be construed as having a quantity of one.

[0032] In this application, "above" or "below" includes the number itself. For example, "below 1" includes 1.

[0033] In this application, room temperature refers to 0~40℃, including but not limited to 10~40℃, or further to 20~30℃.

[0034] The present application will be further illustrated by the following examples, but these examples do not limit the scope of the present application.

[0035] When numerical ranges are given in the embodiments, it should be understood that, unless otherwise stated in this application, both endpoints of each numerical range and any value between the two endpoints may be selected. Unless otherwise defined, all technical and scientific terms used in this application have the same meaning as commonly understood by one of ordinary skill in the art. Where specific conditions are not specified in the embodiments, conventional conditions or conditions recommended by the manufacturer shall apply. All reagents or instruments whose manufacturers are not specified are conventional products that can be purchased commercially. In addition to the specific methods, equipment, and materials used in the embodiments, based on the knowledge of the prior art possessed by one of ordinary skill in the art and the description in this application, any prior art methods, equipment, and materials similar to or equivalent to those described, used, or made by the methods, equipment, and materials in the embodiments of this application may be used to implement this application.

[0036] Preparation Example 1

[0037] Preparation of phase A: Take 0.8g of hyaluronic acid, 0.5g of carboxymethyl chitosan and 0.3g of sodium alginate, mix them and add them to 70g of deionized water. Stir overnight at room temperature to obtain phase A for later use.

[0038] Preparation of phase B: 0.1g triclosan, 0.05g berberine, and 0.05g propyl gallate were added sequentially to 15g anhydrous ethanol and dissolved by ultrasonication at 20kHz. Then, 0.4g tributyl citrate and 0.01g candelilla wax powder were added and ultrasonication was continued for 5min to obtain phase B for later use.

[0039] Preparation Example 2

[0040] Preparation of phase A: Take 1g of hyaluronic acid, 0.6g of carboxymethyl chitosan and 0.3g of sodium alginate, mix them and add them to 70g of deionized water. Stir overnight at room temperature to obtain phase A for later use.

[0041] Preparation of phase B: 0.15g triclosan, 0.1g berberine, and 0.05g propyl gallate were added sequentially to 15g anhydrous ethanol and dissolved by ultrasonication at 22kHz. Then, 0.5g tributyl citrate and 0.02g candelilla wax powder were added and ultrasonication was continued for 10min to obtain phase B for later use.

[0042] Preparation Example 3

[0043] Preparation of phase A: Take 1g of hyaluronic acid, 0.8g of carboxymethyl chitosan and 0.5g of sodium alginate, mix them and add them to 70g of deionized water. Stir overnight at room temperature to obtain phase A for later use.

[0044] Preparation of phase B: 0.2g triclosan, 0.1g berberine, and 0.1g propyl gallate were added sequentially to 15g anhydrous ethanol and dissolved by ultrasonication at 25kHz. Then, 0.5g tributyl citrate and 0.02g candelilla wax powder were added and ultrasonication was continued for 10min to obtain phase B for later use.

[0045] Example 1

[0046] In this embodiment, the preparation process of the antibacterial PDO suture is as follows:

[0047] Take 300g of PPDO granules (intrinsic viscosity 3.2dl·g) -1 After thorough drying, the temperature was set to 130℃ and the screw speed to 25r / min for melt spinning to obtain the precursor yarn. The draw ratio was set to 3.7, and the precursor yarn was drawn. The drawn yarn was then introduced into a plasma corona treatment machine with an electrode plate spacing of 0.42cm, a current intensity of 1.8A, a power of 3000w, and a treatment time of 2.8s. After that, the corona-treated yarn was immersed in a coating solution and treated overnight at 35℃. Finally, after washing and drying, antibacterial PDO sutures with a diameter of 0.37mm were obtained.

[0048] In this embodiment, the preparation steps of the coating liquid are as follows:

[0049] Phase B was slowly added dropwise to phase A at a rate of 1.5 mL / min, while maintaining a stirring speed of 200 r / min for 1 hour. Then, 4.2 mL of a 6% (w / w) chitosan quaternary ammonium salt aqueous solution was added and stirred for 20 minutes. Next, 2 mL of a 3.5% (w / w) dopamine hydrochloride aqueous solution was added and stirring was continued for 30 minutes. The pH was then adjusted to 7.8 using 1M NaOH solution, followed by the addition of 3 mL of a 0.5% (w / w) genipin alcohol solution. The mixture was stirred at room temperature in the dark for 2.5 hours, then transferred to a 4°C refrigerator for 12 hours of curing. Finally, the mixture was filtered through a 200-mesh filter cloth to obtain the coating solution.

[0050] Phase A and Phase B were prepared in Preparation Example 1.

[0051] Example 2

[0052] In this embodiment, the preparation process of the antibacterial PDO suture is as follows:

[0053] Take 300g of PPDO granules (intrinsic viscosity 3.2dl·g) -1 After thorough drying, the temperature was set to 132℃ and the screw speed to 28r / min for melt spinning to obtain the precursor yarn. The draw ratio was set to 4.1, and the precursor yarn was drawn. The drawn yarn was then introduced into a plasma corona machine with an electrode plate spacing of 0.42cm, a current intensity of 2.1A, a power of 3500w, and a treatment time of 3s. After that, the corona-treated yarn was immersed in a coating solution and treated overnight at 37℃. Finally, after washing and drying, antibacterial PDO sutures with a diameter of 0.34mm were obtained.

[0054] In this embodiment, the preparation steps of the coating liquid are as follows:

[0055] Phase B was slowly added dropwise to phase A at a rate of 1.5 mL / min, while maintaining a stirring speed of 200 r / min for 1.5 hours. Then, 4.5 mL of a 6.8% (w / w) chitosan quaternary ammonium salt aqueous solution was added and stirred for 30 minutes. Next, 2.2 mL of a 3.5% (w / w) dopamine hydrochloride aqueous solution was added and stirred for another 30 minutes. The pH was then adjusted to 7.8 using 1M NaOH solution, followed by the addition of 3 mL of a 1% (w / w) genipin alcohol solution. The mixture was stirred at room temperature in the dark for 3 hours, then transferred to a 4°C refrigerator for 12 hours of aging. Finally, the mixture was filtered through a 200-mesh filter cloth to obtain the coating solution.

[0056] Phase A and Phase B were prepared in Preparation Example 2.

[0057] Example 3

[0058] In this embodiment, the preparation process of the antibacterial PDO suture is as follows:

[0059] Take 300g of PPDO granules (intrinsic viscosity 3.2dl·g) -1 After thorough drying, the temperature was set to 135℃ and the screw speed to 30r / min for melt spinning to obtain the precursor yarn. The draw ratio was set to 4.2, and the precursor yarn was drawn. The drawn yarn was then introduced into a plasma corona treatment machine with an electrode plate spacing of 0.4cm, a current intensity of 2.3A, a power of 4000w, and a treatment time of 3.5s. After that, the corona-treated yarn was immersed in a coating solution and treated overnight at 37℃. Finally, after washing and drying, antibacterial PDO sutures with a diameter of 0.33mm were obtained.

[0060] In this embodiment, the preparation steps of the coating liquid are as follows:

[0061] Phase B was slowly added dropwise to phase A at a rate of 2 mL / min, while maintaining a stirring speed of 200 r / min for 2 hours. Then, 4.5 mL of an 8% (w / w) chitosan quaternary ammonium salt aqueous solution was added and stirred for 30 minutes. Next, 2-2.5 mL of a 5% (w / w) dopamine hydrochloride aqueous solution was added and stirred for another 30 minutes. The pH was then adjusted to 8.0 using 1M NaOH solution, followed by the addition of 3.5 mL of a 1% (w / w) genipin alcohol solution. The mixture was stirred at room temperature in the dark for 3 hours, then transferred to a 4°C refrigerator for 12 hours of curing. Finally, the mixture was filtered through a 200-mesh filter cloth to obtain the coating solution.

[0062] Phase A and Phase B were prepared in Preparation Example 3.

[0063] Comparative Example 1

[0064] The difference between this comparative example and Example 1 is that the preparation process of the antibacterial PDO suture is as follows:

[0065] Take 300g of PPDO granules (intrinsic viscosity 3.2dl·g-1), dry them thoroughly, set the temperature to 130℃ and the screw speed to 25r / min, and melt spin to obtain the precursor yarn. Set the draw ratio to 3.7 and draw the precursor yarn. Then immerse the drawn yarn in the coating solution and treat it at 35℃ overnight. Finally, after washing and drying, antibacterial PDO suture with a diameter of 0.37mm is obtained.

[0066] The remaining steps are the same as in Example 1.

[0067] Comparative Example 2

[0068] The difference between this comparative example and Example 1 is that the preparation steps of the coating liquid are as follows:

[0069] Preparation of phase A: Take 0.8g of hyaluronic acid, 0.5g of carboxymethyl chitosan and 0.3g of sodium alginate, mix them and add them to 70g of deionized water. Stir overnight at room temperature to obtain phase A for later use.

[0070] Phase B preparation: 0.1g of triclosan was added to 15g of anhydrous ethanol and dissolved with ultrasonic assistance at 20kHz. Then, 0.4g of tributyl citrate and 0.01g of candelilla wax powder were added and ultrasonication was continued for 5min to obtain phase B for later use.

[0071] Phase B was slowly added dropwise to phase A at a rate of 1.5 mL / min, while maintaining a stirring speed of 200 r / min for 1 hour. Then, 2 mL of a 3.5% (w / w) dopamine hydrochloride aqueous solution was added, and stirring was continued for 30 minutes. The pH was then adjusted to 7.8 using 1M NaOH solution, followed by the addition of 3 mL of a 0.5% (w / w) genipin alcohol solution. The mixture was stirred at room temperature in the dark for 2.5 hours, then transferred to a 4°C refrigerator for 12 hours of aging. Finally, the mixture was filtered through a 200-mesh filter cloth to obtain the coating solution.

[0072] The remaining steps are the same as in Example 1.

[0073] Performance testing

[0074] 1. Degradation test

[0075] Preparation of simulated degradation solution: Weigh 8.00g NaCl, 0.20g KCl, 1.44g Na2HPO4, and 0.24g KH2PO4, add 1000mL deionized water, stir until completely dissolved, and finally sterilize with ultraviolet light to obtain the solution.

[0076] Take 5g of each of the PDO suture samples from Examples 1-3 and Comparative Examples 1-2 and dry them in a vacuum drying oven until constant weight. Record the mass (W0) at this point. Then, completely immerse each group of sutures in simulated degradation solution and conduct degradation experiments under extreme conditions at (42±1)℃ with constant temperature oscillation (oscillation rate 200r / min). The test period is 28 days. After periodically removing the samples and drying them to constant weight, record the mass (W1) at this point. Calculate the weight loss rate η according to the following formula:

[0077]

[0078] The change in weightlessness rate over time was obtained, and the results are as follows: Figure 1 As shown.

[0079] Take Examples 1-3 and Comparative Examples 1-2 and combine them. Figure 1It can be concluded that, based on the weight loss curve trend before 21 days, the weight loss rate curves of Examples 1-3 and Comparative Example 2 showed relatively stable trends, indicating a slower degradation rate of the suture. In contrast, the weight loss rate of Comparative Example 1 started at 0.5% from 14 days, reaching 1.79% at 21 days, significantly higher than the data of the other groups. This indicates that the PDO matrix inside the suture of Comparative Example 1 had begun to be consumed at this time. Due to the adhesion problem between the coating and the PDO matrix, the coating of the suture in Comparative Example 1 detached more rapidly under the oscillation disturbance of the experimental environment, leading to premature degradation and loss of the protected PDO matrix. After 21 days, due to the loss of the coating, the inner PDO matrix with poor hydrolysis resistance was exposed. Therefore, Examples 1-3 and Comparative Examples 1-2 both showed a rapid increase in weight loss rate. However, from the overall trend of the weight loss rate change curve over time, the suture prepared after treatment using the example scheme showed excellent degradation resistance.

[0080] 2. Durable antibacterial test

[0081] During the degradation of the suture coating, triclosan, as an antibacterial active ingredient, is continuously released. By quantitatively detecting the cumulative release of triclosan during the test period, the durable antibacterial performance of the coating can be indirectly evaluated.

[0082] Take 5g of PDO suture samples from Examples 1-3 and Comparative Examples 1-2 respectively, rinse three times with deionized water, and dry thoroughly. Then, scrape off the surface coating with a scraper, collect the scraped material, and sonicate it in methanol solution for 1 hour to obtain methanol dispersions. Finally, measure the absorbance of each group of methanol dispersions at a wavelength of 280nm using ultraviolet spectroscopy, and record it as A0. Similarly, take the PDO suture samples from each group of degradation test groups and measure the absorbance to obtain the absorbance value, which is recorded as A1. According to the formula:

[0083]

[0084] Where W represents the cumulative release percentage of triclosan, and the test results are as follows: Figure 2 As shown.

[0085] Take Examples 1-3 and Comparative Examples 1-2 and combine them. Figure 2 It can be concluded that after degradation testing, triclosan in Examples 1-3 and Comparative Examples 1-2 was consumed to varying degrees. Among them, the average cumulative release of triclosan in the Example schemes was 34.32%, which was significantly lower than 67.75% in Comparative Example 1 and 52.69% in Comparative Example 2. In Comparative Example 1, the release of triclosan was too rapid due to the large loss of the triclosan carrier coating during the degradation test. In Comparative Example 2, the release rate was also at a high level due to the lack of triclosan slow-release components. The antibacterial effect was not long-lasting.

[0086] Although this application has been described in detail with reference to the foregoing embodiments, those skilled in the art can still modify the technical solutions described in the foregoing embodiments or make equivalent substitutions for some of the technical features. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of this application should be included within the protection scope of this application.

Claims

1. A process for preparing an antibacterial PDO suture, characterized in that, Includes the following steps: PPDO granules are taken, thoroughly dried, and then melt-spun. The granules are then subjected to drawing, corona treatment, and impregnation treatment in sequence, followed by washing and drying with water to obtain the final product. The impregnation treatment is carried out in a coating solution. The preparation steps of the coating liquid include the following: S01. Take hyaluronic acid, carboxymethyl chitosan and sodium alginate, mix them, add water to disperse them, stir at room temperature overnight to obtain phase A for later use; S02. Mix triclosan, alkali, and propyl gallate, add ethanol and sonicate to disperse, then add tributyl citrate and candelilla wax powder, continue sonication to obtain phase B for later use; S03. Add phase B dropwise to phase A, then add chitosan quaternary ammonium salt aqueous solution, stir, then add dopamine hydrochloride aqueous solution, continue stirring, then adjust the pH, add genipin alcohol solution, stir the reaction in the dark, then cure at 4°C, and filter with 200 mesh filter cloth to obtain the final product.

2. The preparation process of an antibacterial PDO suture according to claim 1, characterized in that, The melt spinning setting is a spinning temperature of 130℃-135℃ and a screw speed of 25-30 r / min; the drawing setting is a drawing ratio of 3.7-4.

2.

3. The preparation process of an antibacterial PDO suture according to claim 1, characterized in that, The corona treatment is set with a current intensity of 1.8-2.3A, a power of 3000-4000W, and a corona treatment time of 2.8-3.5s.

4. The preparation process of an antibacterial PDO suture according to claim 1, characterized in that, In step S01, the mass-to-volume ratio of hyaluronic acid, carboxymethyl chitosan, sodium alginate and water is (0.8-1)g:(0.5-0.8)g:(0.3-0.5)g:70mL.

5. The preparation process of an antibacterial PDO suture according to claim 1, characterized in that, In step S02, the mass-to-volume ratio of triclosan, alkali, propyl gallate, ethanol, tributyl citrate, and candelilla wax powder is (0.1-0.2)g:(0.05-0.1)g:(0.05-0.1)g:15mL:(0.4-0.5)g:(0.01-0.02)g.

6. The preparation process of an antibacterial PDO suture according to claim 1, characterized in that, In step S02, the ultrasonic power is set to 20-25kHz.

7. The preparation process of an antibacterial PDO suture according to claim 1, characterized in that, In step S03, the dropping rate of phase B is controlled to be 1.5-2 mL / min.

8. The preparation process of an antibacterial PDO suture according to claim 1, characterized in that, In step S03, the mass concentration of chitosan quaternary ammonium salt in the chitosan quaternary ammonium salt aqueous solution is 6%-8%; the concentration of dopamine hydrochloride in the dopamine hydrochloride aqueous solution is 3.5%-5%; and the mass concentration of genipin in the genipin alcohol solution is 0.5%-1%.

9. The preparation process of an antibacterial PDO suture according to claim 1, characterized in that, In step S03, the pH is adjusted to 7.8-8.

0.

10. An antibacterial PDO suture, characterized in that, It is prepared using the preparation process described in any one of claims 1-9.

Images